US4353905A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones
Assignee: Warner Lambert Co LLC
•
Filing: 1981-09-17
•
Granted: 1982-10-12
•
Expires: 2001-09-17
Abstract
Abstract Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)-phenyl]-3(2H)-pyridazinone compounds and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinone compounds and pharmaceutically acceptable salts thereof are useful as cardiotonic agents. Said compounds cause a significant increase in myocardial contractility in the anesthetized dog. Said compounds are produced by reacting substituted γ-oxo-benzenebutanoic acids with suitably substituted hydrazines to provide 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones which are dehydrogenated to 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones. Both the intermediate 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and the 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones are useful as cardiotonic agents.
Inventors
- 👤 Ila Sircar
- 👤 James A. Bristol
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 02:48
CPC Classifications
C; C07; C07D; C07D231/00; C07D231/02; C07D231/10; C07D231/12; A; A61; A61P; A61P9/00; A61P9/12; C07D233/00; C07D233/54; C07D233/56; C07D249/00; C07D249/02; C07D249/08
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
72 words
A compound having the structural formula: ##STR4## wherein represents a double or single bond between two carbon atoms; R 1 and R 1 ' are independently hydrogen, lower alkyl, CH 2 C 6 H 5 or C 6 H 5 ; R 2 is hydrogen, lower alkyl or 2-hydroxyethyl; and R 3 is hydrogen or lower alkyl wherein lower alkyl has one to six carbon atoms; and the pharmaceutically acceptable salts thereof.
Claim 2
Dependent Claim
72 words
A compound having the structural formula: ##STR4## wherein represents a double or single bond between two carbon atoms; R 1 and R 1 ' are independently hydrogen, lower alkyl, CH 2 C 6 H 5 or C 6 H 5 ; R 2 is hydrogen, lower alkyl or 2-hydroxyethyl; and R 3 is hydrogen or lower alkyl wherein lower alkyl has one to six carbon atoms; and the pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim
35 words
A compound according to claim 1 having the structure: ##STR5## wherein R 1 , R 1 ', R 2 , and R 3 are as defined in claim 1, and the pharmaceutically acceptable salts thereof.
Claim 4
Dependent Claim
35 words
A compound according to claim 1 having the structure: ##STR6## wherein R 1 , R 1 ', R 2 , and R 3 are as defined in claim 1, and the pharmaceutically acceptable salts thereof.
Claim 5
Dependent Claim
9 words
A compound according to claim 2 which is 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinone.
Claim 6
Dependent Claim
9 words
A compound according to claim 3 which is 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinone.
Claim 7
Independent Claim
95 words
The method for increasing cardiotonic contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient an effective amount of a compound having the structure: ##STR7## wherein represents a single or double bond between two carbon atoms; R 1 , and R 1 ' are independently hydrogen, lower alkyl, CH 2 C 6 H 5 or C 6 H 5 ; R 2 is hydrogen, lower, alkyl, 2-hydroxyethyl; R 3 is hydrogen or lower alkyl; or a pharmaceutically acceptable acid addition salt thereof.
Claim 8
Independent Claim
95 words
The method for increasing cardiotonic contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient an effective amount of a compound having the structure: ##STR7## wherein represents a single or double bond between two carbon atoms; R 1 , and R 1 ' are independently hydrogen, lower alkyl, CH 2 C 6 H 5 or C 6 H 5 ; R 2 is hydrogen, lower, alkyl, 2-hydroxyethyl; R 3 is hydrogen or lower alkyl; or a pharmaceutically acceptable acid addition salt thereof.
References Cited (Backward Citations)
US4088762A
Cited
DE2151216A1
Cited
US3845050A
Cited
US4251658A
Cited
JPS5419987A
Cited
EP0008391A1
Cited
US4301169A
Cited
GB2057438A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-10-11 | 1986-04-12 | 1986-10-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-10-11 | 1990-04-12 | 1990-10-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-10-11 | 1994-04-12 | 1994-10-12 | $7700.00 | Window Closed / Lapsed |